155 results
8-K
EX-99.1
FBIO
Fortress Biotech Inc
15 May 24
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
4:20pm
with subjects completing the 16-week treatment with no significant safety issues. DFD-29 demonstrated statistical superiority compared to both Oracea capsules … manufacturing organization as approvability issues to address in a resubmission. The CRL did not state any concerns about the clinical data package, safety
8-K
EX-99.1
FBIO
Fortress Biotech Inc
28 Mar 24
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
4:10pm
. The CRL did not state any concerns about the clinical data package, safety or labeling for the approvability of cosibelimab. We believe we can address … -label, multicenter clinical trial to assess the safety, tolerability and efficacy of MB-109, a novel combination of MB-101 (IL13Rα2-targeted CAR-T cell
8-K
EX-10.1
nlr0m4pe6i3p3x 82dt
3 Jan 24
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:10pm
8-K
EX-10.1
yhvjp2
14 Nov 23
Fortress Biotech Announces Launch of Proposed Public Offering
4:11pm
8-K
EX-99.1
h96kn06 et2ev
14 Aug 23
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:08pm
8-K
EX-99.1
i5wv9j1sp
15 May 23
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
5:05pm
8-K
EX-99.1
436wvshru92psk
30 Mar 23
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
5:28pm
8-K
EX-99.1
qk8yl6 9ll
14 Nov 22
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
5:02pm
8-K
EX-99.1
2d39ft00cgnnd4cllwge
11 Aug 22
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
4:46pm
8-K
EX-99.1
0uyh euzr6v
12 May 22
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
4:16pm